Mass primaquine treatment to eliminate vivax malaria: lessons from the past

by Anatoly Kondrashin, Alla M Baranova, Elizabeth A Ashley et al.
Malaria Journal 2014, 13:51 (7 February 2014)

34 pp. 2.4 MB:
http://www.malariajournal.com/content/pdf/1475-2875-13-51.pdf

A significant obstacle to malaria elimination in Asia is the large burden of Plasmodium vivax, which is more difficult to eliminate than Plasmodium falciparum. Persistent P. vivax liver stages can be eliminated only by radical treatment with a seven-day course of an 8-aminoquinoline, with the attendant risk of acute haemolytic anaemia in individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency. This report shows that with careful planning and implementation of mass treatment strategies using primaquine and adequate medical support to manage haemolytic toxicity, it is possible to achieve high population coverage, substantially reduce malaria transmission, and manage the risk of severe acute haemolytic anaemia in communities with a relatively high prevalence of G6PD deficiency safely.

(Visited 16 times, 1 visits today)
This entry was posted in General, Malaria. Bookmark the permalink.